



April 25, 2016



## Adimab Expands Bispecific Antibody Offering with Novel CD3 Program

**Lebanon, NH – April 25, 2016** – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has used its proprietary antibody discovery technology to generate multiple new anti-CD3 binders which are available for out-licensing. Adimab also announced that it has expanded its collaboration with two current partners to include access to these novel anti-CD3 binders.

Adimab's CD3 program consists of a panel of fully human antibodies against CD3; the binders were originally discovered using Adimab's proprietary B cell isolation process and then significantly enhanced using Adimab's optimization capabilities. Adimab will be licensing these anti-CD3 binders on a non-exclusive basis for use in bispecific antibodies, with binding partners coming either from Adimab or its licensees.

Under the terms of the aforementioned agreements, each partner has the ability to incorporate Adimab's anti-CD3 binders into their own therapeutic bispecific molecules, or have Adimab design anti-CD3-based bispecifics for them.

"Our novel CD3 program expands the range of solutions we can offer to our partners," said Guy Van Meter, Vice President of Business Development of Adimab. "Bispecific therapeutics are a very important aspect of our business and our new CD3 program, as well as our common light chain capabilities, have been of significant interest to many of our partners."

"Adimab continues to evolve and improve the platform, with the goal to be the industry's premier independent technology provider in the antibody discovery space for the next decade. Adimab is not pursuing an internal product pipeline, and therefore focuses significant effort on technology development and improvements," said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "Adimab's new B cell isolation process combined with the Adimab

optimization capabilities can be applied to very challenging targets and still allow for dramatic enhancements to potential leads. This new approach will enable the generation of therapeutic programs for a broader range of targets. "

Over the past seven years, Adimab has established funded discovery collaborations with over 35 companies. Adimab's funded discovery partners include Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others, as well as academic institutions such as Memorial Sloan Kettering and MD Anderson. In addition to funded discovery programs, the Adimab antibody discovery and optimization platform and custom antibody libraries have been transferred to Merck, Novo Nordisk, Biogen, and GSK for internal use.

## **About Adimab**

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit <http://www.adimab.com>.

Guy Van Meter  
VP of Business Development  
Adimab, LLC  
(603) 653-5775  
[guy.vanmeter@adimab.com](mailto:guy.vanmeter@adimab.com)